Metabolic research has moved fast from single-receptor GLP-1 agonists to dual and triple-agonist sequences within the space of a few years, and the catalog names can blur together if you're not tracking which compound targets which receptor combination. Here's a straight side-by-side of the six metabolic-pathway peptides in our catalog, grouped by how many receptors each one engages.
Single-pathway: Semaglutide
Semaglutide is a GLP-1 receptor agonist analog and the field's most-referenced single-pathway compound — the baseline most comparative protocols measure newer multi-agonist sequences against. Analytical-grade, 99.91% HPLC purity, verified by HPLC and mass spectrometry prior to release.
Dual-pathway: Tirzepatide, Survodutide & Mazdutide
Three compounds in our catalog target two receptors simultaneously, each with a different combination:
- Tirzepatide — dual GIP/GLP-1 agonist, 99.88% HPLC purity, with mass-spectrometry-confirmed molecular identity per batch.
- Survodutide — dual glucagon/GLP-1 agonist, 99.79% HPLC purity, used to study combined energy-expenditure and appetite-regulation pathways.
- Mazdutide — also dual GLP-1/glucagon, 99.81% HPLC purity, examined in metabolic pathway and energy-balance research models.
Triple-pathway: Retatrutide (RTA GLP-3)
Retatrutide is the only triple agonist in the catalog, engaging GIP, GLP-1, and glucagon receptors in one sequence — developed specifically as a research tool for studying combined incretin-receptor pathway activity. 99.75% HPLC purity, with a published Certificate of Analysis per batch.
Adjacent pathway: Cagrilintide
Cagrilintide isn't a GLP-1 agonist at all — it's a long-acting amylin receptor agonist, studied for its role in satiety-signaling pathways. It's included here because it's frequently examined alongside GLP-1 agonists in combined-pathway research designs. 99.83% HPLC purity, HPLC and mass-spec verified before release.
Choosing a starting point
If your protocol is establishing a baseline, Semaglutide remains the standard reference. If you're studying combined-receptor effects, the dual agonists let you isolate which second pathway (GIP, glucagon, or amylin via Cagrilintide) is driving the difference you're seeing. Retatrutide is generally the endpoint comparison once a triple-pathway model is warranted.